Cellectar
在场
高管
查看带有其 13 名主要高管的组织结构图
Cellectar 搜索最多的简介
- James Caruso, President, Chief Executive Officer and Director
- John Neis, Director
- Douglas Swirsky, Chairman of the Board
高管在Cellectar变化
- William Yoon已作为Vice President and Head of Medical Affairs加入公司 (新闻发布的2023十月17号).
- Aaditya Nanduri已作为Vice President, Business Strategy and Analytics加入公司 (新闻发布的2023十月17号).
创建提醒
跟踪 Cellectar 的高管变动
生物技术
Cellectar 拥有 2,275 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
- Nurix Therapeutics 刚刚宣布为 175 筹款数百万美元。 (公布2024四月13号).
生物技术 行业的其他推荐联系人
消息
Cellectar 的最新新闻稿
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
- Cellectar Biosciences to Present at the 36th Annual Roth Conference
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
- Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Press Releases
- Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
- Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
- View more press releases Close
关于 Cellectar 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 James Caruso 
